• 디지털융복합연구
• /
• 제20권5호
• /
• pp.323-329
• /
• 2022

본 연구에서는 강원 춘천시 봄내체육관에 설치된 신종 코로나바이러스 예방접종 센터를 예방접종을 위한 임시공간 사인 시스템을 활용하여 행사장을 위해 설계된 사인 시스템 이용자를 평가하였다. 임시공간의 간판체계는 일반 공간과 달리 공간이 한정된 일정으로 구성되기 때문에 공간정보와 간판디자인 진행상황에 대한 정보를 적절히 배열해 사용자에게 전달할 필요가 있다. 이에 종이 사용설명서, 벽면 전광판, 바닥 면 경로 테이프 등이 백신 접종장 이용자를 위한 간판 시스템으로 제공 및 배치된다. 사용자 평가 결과 60세 이상 특정 사용자의 경우 공간과 과정에 대한 전반적인 정보를 전달하는 문서(정보식별시스템)가 백신 접종에 효과적인 것으로 나타났다. 이 결과는 향후 임시공간에 사인 시스템을 구축할 때 설치 방법 및 제작에 참고가 될 것으로 기대된다.

• Journal of Preventive Medicine and Public Health
• /
• 제56권2호
• /
• pp.172-179
• /
• 2023

Objectives: Vaccination is an important intervention for preventing disease and reducing disease severity. Universal vaccination programs have significantly reduced the incidence of many dangerous diseases among children worldwide. This study investigated the side effects after immunization in infants under 1 year of age in Lorestan Province, western Iran. Methods: This descriptive analytical study included data from all children <1 year old in Lorestan Province, Iran who were vaccinated according to the national schedule in 2020 and had an adverse event following immunization (AEFI). Data were extracted from 1084 forms on age, sex, birth weight, type of birth, AEFI type, vaccine type, and time of vaccination. Descriptive statistics (frequency, percentage) were calculated, and the chi-square test and Fisher exact test were used to assess differences in AEFIs according to the abovelisted variables. Results: The most frequent AEFIs were high fever (n=386, 35.6%), mild local reaction (n=341, 31.5%), and swelling and pain (n=121, 11.2%). The least common AEFIs were encephalitis (n=1, 0.1%), convulsion (n=2, 0.2%), and nodules (n=3, 0.3%). Girls and boys only showed significant differences in mild local reactions (p=0.044) and skin allergies (p=0.002). The incidence of lymphadenitis (p<0.001), severe local reaction (p<0.001), mild local reaction (p=0.007), fainting (p=0.032), swelling and pain (p=0.006), high fever (p=0.005), and nodules (p<0.001) showed significant differences based on age at vaccination. Conclusions: Immunization is a fundamental public health policy for controlling vaccine-preventable infectious diseases. Although vaccines such as the Bacillus Calmette-Guérin vaccine, oral poliovirus vaccine, and pentavalent vaccine are well-researched and reliable, AEFIs are inevitable.

• Journal of Preventive Medicine and Public Health
• /
• 제18권1호
• /
• pp.51-57
• /
• 1985

To attempt to measure the effect of domestic product P.H.A. kit 'Hepa-S' after completion of 'Hepa-Vax' vaccination schedule, P.H.A. test and R.I.A. test on the 330 healthy adults were carried out. The results obtained were as follow ; 1. The positive anti HBs rate after completion of 'Hepa-Vax' vaccination were; in P.H.A. test with domestic product P.H.A. kit 81.2%, in P.H.A. test with foreign product P.H.A. kit 82.7%, and in R.I.A. test 95.8% 2. Using the result of R.I.A. test as the standard, sensitivity of P.H.A. test with domestic product P.H.A. kit was 84.8% and specificity was 100.0% 3. Using the result of R.I.A. test as standard, sensitivity of P.H.A. test with foreign P.H.A. kit was 86.4% and specificity was 100.0%. 4. The concordance rate of P.H.A. test with domestic product and foreign product kit was 98.5%. On the result of this study, there was no significant difference in the validity between the domestic product P.H.A. kit 'Hepa-S' and the foreign P.H.A. kit $'Hebsgencell^{TM}'$. So that it is recommendable to use domestic product P.H.A. kit instead of foreign product P.H.A. kit.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권8호
• /
• pp.3435-3442
• /
• 2015

Objective : To provide background information for strengthening cervical cancer prevention in the Pacific by mapping current human papillomavirus (HPV) vaccination and cervical cancer screening practices, as well as intent and barriers to the introduction and maintenance of national HPV vaccination programmes in the region. Materials and Methods: A cross-sectional questionnaire-based survey among ministry of health officials from 21 Pacific Island countries and territories (n=21). Results: Cervical cancer prevention was rated as highly important, but implementation of prevention programs were insufficient, with only two of 21 countries and territories having achieved coverage of cervical cancer screening above 40%. Ten of 21 countries and territories had included HPV vaccination in their immunization schedule, but only two countries reported coverage of HPV vaccination above 60% among the targeted population. Key barriers to the introduction and continuation of HPV vaccination were reported to be: (i) Lack of sustainable financing for HPV vaccine programs; (ii) Lack of visible government endorsement; (iii) Critical public perception of the value and safety of the HPV vaccine; and (iv) Lack of clear guidelines and policies for HPV vaccination. Conclusion: Current practices to prevent cervical cancer in the Pacific Region do not match the high burden of disease from cervical cancer. A regional approach, including reducing vaccine prices by bulk purchase of vaccine, technical support for implementation of prevention programs, operational research and advocacy could strengthen political momentum for cervical cancer prevention and avoid risking the lives of many women in the Pacific.

• Pediatric Infection and Vaccine
• /
• 제3권2호
• /
• pp.185-193
• /
• 1996

Purpose : The incidence of measles was gradually decreased since 1963 when measles vaccination was firstly developed and liscenced in the world. But, recently the outbreaks of measles in infants and school children have been reported despite of wide spread use of measles vaccination. This study was performed to evaluate the efficacy of measles vaccination and the necessity of revaccination in Korean infants and children. Methods : 168 subjects of mothers and neonates, infants and children were enrolled in this study during the periods of 10 months from March to December in 1995. Measles specific IgG in the sera of mothers and children was measured using EIA kit (Sigma Co., MO, USA). Antibody titer of over or equal to 110 AU/ml was considered positive. Results : The results obtained were as follows. 1) Values of measles specific IgG in the sera of mother and neonate were 82.9 AU/ml and 89.3 AU/ml respectively and were rapidly decreased within 6 month after birth. Positive antibody levels (${\geq}$ 110 AU/ml) were observed in only 25 % of neonates. 2) In vaccinated children, values of measles specific IgG were 117.4 AU/ml in 9~15 month group, 76.9 AU/ml in 3~6 year group and 79.5 AU/ml in 10~15 year group after either one or two times of measles vaccination. Positive antibody levels in vaccinated children were observed in 57.7% of 9~15 month group, 38.4% of 3~6 year group and 34.7% of 10~15 year group. Conclusion : These results suggest that primary measles vaccination before 6 months of age can be considered and revaccination of measles should be recommended before 3~6 years of age. Further studies will be needed to clarify the reasons of high proportion of primary measles vaccination failure and to established the appropriate schedule of measles vaccination in korean infants and children.

• Pediatric Infection and Vaccine
• /
• 제7권1호
• /
• pp.136-142
• /
• 2000

목 적 : 혈장백신의 항체의 지속성에 관한 보고는 다양하지만, 유전자재조합 백신의 추적관찰에 대한 연구는 많지 않아 저자들은 신생아시기에 유전자재조합 백신을 기본접종 후 접종방법에 따른 5년 후 항체의 지속성과 기본접종 후 각각의 항체역가에 따른 5년 후 항체음전율에 대해 알아보고자 본 연구를 시도하였다. 방 법 : 1993년 4월부터 12월까지 부산 문화병원에서 태어난 신생아 420례중 유전자재조합 백신을 기본접종 후 5년까지 추적관찰이 가능했던 114례를 대상으로 하였다. 기본접종 후와 5년 후 항체역가의 검사는 RIA로 시행하였다. 결 과 : 1) 2개월 접종을 하였을 경우 5년째 항체음성률은 5%이고, 6개월 접종을 하였을 경우 5년째 항체 음성률은 25.5%이었다(P value <0.05). 2) 2개월접종시 항체역가가 199.9 이하시 5%, 200~499.9시 0%, 500~999.9시 0%, 1,000 이상시 0%가 5년 추적검사시 항체음전이 되었다. 3) 6개월 접종시 항체역가가 199.9 이하시 66.7%, 200~499.9시 40%, 500~999.9시 23.9%, 1,000 이상시 22.5%가 5년 추적검사시 항체음전이 되었다. 결 론 : 이 연구에서는 유전자재조합 백신의 5년후 항체음전율은 5~25.5%였고, 항체가의 지속성은 접종방법과는 통계학저인 유의성을 보이지 않았고, 기본접종 후의 항체역가에 따른 5년 후 항체음전율과도 통계학적인 유의성은 보이지 않았다.

• Pediatric Infection and Vaccine
• /
• 제20권3호
• /
• pp.115-122
• /
• 2013

Reemerging infectious diseases are infections that had decreased in incidence in the global population and were brought under control through effective health care policy such as vaccination, but more recently, began to resurge as a health problem due to many reasons. Measles, rubella, mumps and pertussis are the examples. Immunization with MMR (measles, mumps, rubella) and pertussis vaccine has contributed to marked decrease in measles, mumps, rubella and pertussis incidence worldwide. In Korea, measles and rubella almost disappeared after the introduction of 2 doses of MMR immunization schedule. Recently, these infections have been reemerging in many countries with low vaccination rates and can be introduced again in Korea. However mumps and pertussis outbreaks are reported among fully vaccinated populations. Declining vaccine effectiveness, an increased awareness and surveillance of the disease or improved laboratory diagnostic tools had been suggested as possible causes. For the clinicians, it is difficult to diagnose these reemerging infectious diseases partly because of few experience of typical cases of measles and rubella or partly because of modification of clinical symptoms and signs of infectious diseases in immunized population. In this article, the diagnosis of measles, mumps, rubella and pertussis will be reviewed in the aspects of clinical characteristics, serologic methods, virus isolation, and polymerase chain reaction.

• Childhood Kidney Diseases
• /
• 제6권2호
• /
• pp.198-208
• /
• 2002

목적 : 소아 신증후군을 비롯한 신질환 환아는 질병 자체에 의해서 뿐만 아니라 면역억제제 사용으로 인한 면역 기능 저하로 감염되기 쉬운 상태에 있다. 폐구균 감염, b형 헤모필루스 인플루엔자, 대장균 등에 의한 복막염, 패혈증에 취약한 상태이고 홍역 및 수두 등에 심한 임상 경과를 취하므로 이들 질환에 대한 적극적 예방접종이 필요하며, 미세변화형 신증후군의 호발 연령인 $2{\sim}6$세는 소아의 기본 예방접종의 추가 접종 시기에 속한다. 하지만 신증후군 환아에서 예방접종의 효과 및 부작용에 대해서는 아직 다수의 소아를 대상으로 한 전향적 연구가 없을 뿐만 아니라 임상 경과의 시기, 스테로이드 제제의 사용 용량에 따른 예방접종 시기에 대해서도 완전한 의견의 일치를 보이고 있지 못하고있다. 이러한 문제점을 해결하기 위하여 우선 소아 신장학 분야의 전문가들에 있어서 행해지고 있는 예방접종 실태를 파악하고자 하였다. 대상 및 방법 : 대한소아신장학회에 등록된 정회원 56명을 대상으로 설문 조사를 시행하였다. 결과 : 대상자 56명 중 35명이 응답하였고 (응답률 62.5%), 이중 대학병윈 근무자가 29명(82.8%)이었다. 신증후군 소아에 대한 기본 예방접종은 응답자 35명 모두 일반 소아에서 추천되는 지침과는 다른 수정된 방식으로 예방접종을 실시하고 있었다. 생백신의 경우 관해 이후 고용량 스테로이드 사용 중에 접종하는 경우는 없었으며 저용량 스테로이드 사용 중에 접종하는 경우가 12명(24.3%), 스테로이드 끊고 일정 기간 지난 후 접종이 23명(65.7%)이었다. 사백신의 경우는 관해 이전에도 접종하는 경우가 5명(14.3%), 관해 이후 고용량 스테로이드 사용 중에 접종하는 경우가 5명(14.3%), 저용량 스테로이드 사용 중에 접종하는 경우가 20명(57.1%). 스테로이드 끊고 일정 기간 지난 후 접종하는 경우가 5명(14.3%)이었다. 신질환 소아에서 추천되는 b형 헤모필루스 인플루엔자, B형 간염, 폐구균, 독감 등의 예방접종은 신질환 소아 및 면역억제요법을 실시하지 않는 신부전 소아에게 이들 백신을 대부분 접종하겠다고 응답하였다. 스테로이드사용 중인 신질환 소아에서 이들 예방접종시기에 대해서는 응답자 25명(71.4%)이 저용량 스테로이드 사용 중에 접종하고 있었으며, 단 b형 헤모필루스 인플루엔자는 저용량 스테로이드 투여 시 접종하겠다는 응답자가 18명(45.7%)으로 스테로이드 끊고 접종하겠다는 응답자 15명(42.9%)과 비슷하였다. 신증후군 소아에서 예방접종 후 부작용은 백신 접종 후 신증후군 재발을 경험한 응답자가 9명, 백신접종에도 불구 해당 질병 발병을 경험한 접종자가 3명, 생백신 접종 후 백신 균주에 의한 발병을 경험한 접종자가 2명이었다. 결론 : 국내의 소아 신장학 전문가들은 일반 소아에서 권장되는 예방접종 지침과는 다른 수정된 방식에 따른 예방접종을 실시하고 있었으나 아직 질병 경과와 스테로이드 사용에 따른 접종 시기에 다양성을 보이고 있었고, 또한 예방접종 후의 부작용을 경험한 경우도 다수 있었다. 따라서 향후 다수의 소아를 대상으로 한 전향적인 연구를 통하여 소아 신질한 환아에서 추천되는 예방접종 지침을 확립할 필요가 있다고 사료된다.

• 대한미생물학회지
• /
• 제22권4호
• /
• pp.473-483
• /
• 1987

Present study was undertaken to find when is right time for vaccination against Measles, Mumps and Rubella and what is the seropositive conversion rate after those vacinations. For this purpose, sera from 106 infants and children adimitted in Prediatric Department of Won Kwang University Hospital, Iri, Chonbuk, Korea were divided into 3 groups, such as (1) Vaccination group with definite information when it was given, (2) Unknown group whether vaccination was given or not, (3) Not vaccinated group. They were tested of IgG and IgM antibodies against Measles, Mumps and Rubella using Enzyme Immunoassay method and the following results were obtained. 1. Infants below 6 month of age showed to have IgG antibodies which seemed to have been transferred from mother in 87.8%(29/33) for Measles, 78.8%(26/33) for Mumps and 39.4%(13/13) for Rubella. And they showed IgM antibodies which are thought to have been produced by recent infection in 24.2%(8/33) for Measles, 48.5%(16/33) for Mumps and 9.1%(3/33) for Rubella. 2. Positivity of antibody IgG against Rubella was observed remarkably lower than it is against Measles and Mumps being only 39.4%(13/33) in $0{\sim}5$ month, 30.8%(8/26) in $6{\sim}11$ months, 30%(3/10) in $12{\sim}14$ months and 62.9%(22/35) in $18{\sim}36$ months of age. 3. ${\Delta}OD's$ of IgG and IgM antibodies against Measles were observed increasing with age being 0.444, 0.220 in $0{\sim}5$ months, 0.326, 0.134 in $6{\sim}11$ months, 0.581, 0.140 in $12{\sim}14$ months, 0.512, 0.000 in $15{\sim}17$ months and 0.887, 0.278 in $18{\sim}36$ months of age, respectively. 4. ${\Delta}OD's$ of IgG and IgM antibodies against Mumps were observed increasing with age being 0.427, 0.340 in $0{\sim}5$ months, 0.400, 0.249 in $6{\sim}11$ months, 0.694, 0.314 in $12{\sim}14$ months, 0.539, 0.165 in $15{\sim}17$ months and 0.854, 0.350 in $18{\sim}36$ months of age, respectively. 5. Vaccination for Measles, Mumps and Rubella is generally to start at 15 months of age in Korea, by which age their antibodies are found to exsist in more than 80% of tested samples. So, it seems to be very reasonable to start the vaccination schedule at earlier age than it does currently. 6. From the present study, it seems to have been clearly confirmed that Enzyme Immunoassay method is a reliable method with good reproducibility for mass survey of IgG and IgM antibodies against Measles, Mumps and Rubella in infants and children.

• Clinical and Experimental Pediatrics
• /
• 제59권12호
• /
• pp.461-465
• /
• 2016

This report includes the recommended immunization schedule table for children and adolescents based on the 8th (2015) and revised 7th (2012) Immunization Guidelines released by the Committee on Infectious Diseases of the Korean Pediatric Society (KPS). Notable revised recommendations include: reorganization of the immunization table with a list of vaccines on the vertical axis and the corresponding age on the horizontal axis; reflecting the inclusion of Haemophilus influenzae type b vaccine, pneumococcal conjugate vaccine, and hepatitis A vaccine into the National Immunization Program since 2012; addition of general recommendations for 2 new Japanese encephalitis (JE) vaccines and their interchangeability with existing JE vaccines; addition of general recommendations for quadrivalent meningococcal conjugate vaccines and scope of the recommended targets for vaccination; and emphasizing catch-up immunization of Tdap vaccine. Detailed recommendations for each vaccine may be obtained from the full KPS 8th Immunization Guidelines.